Evidence map›Paper›PMID 42446114›Full record

ArticleHematological oncology2026

Low-Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T-Cell Acute Lymphoblastic Leukemia: A Case Series.

Shen-Hao Liu, Ai-Ni Deng, Hui-Ying Li, Qian Wang, Yang Li, Zi-Fan Zheng, Si-Man Huang, Han-Yu Cao, Chao-Ling Wan, Xiao-Hui Hu and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shen-Hao LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0009-0008-0665-460X
Ai-Ni DengNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hui-Ying LiNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qian WangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yang LiNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zi-Fan ZhengNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Si-Man HuangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Han-Yu CaoNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0003-3022-6935
Chao-Ling WanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiao-Hui HuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hai-Ping DaiNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Sheng-Li XueNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0003-4609-616X

Funding

Boxi Clinical Research Project BXLC008Boxi Clinical Research Project BXLC2024009Jiangsu Province "333" Project, Social Development Project of the Science and Technology Department of Jiangsu BE2021649Jiangsu Province Natural Science Foundation of China BK20221235National Key Research and Development Program of China 2022YFC2502700National Natural Science Foundation of China 81970138National Natural Science Foundation of China 82270165National Natural Science Foundation of China 82470174
6 · The paper itself

Abstract

Post-transplant relapse remains a major challenge in T-ALL, with limited effective salvage options. We report on eight T-ALL patients who received low-dose chidamide (5 mg once weekly) as maintenance therapy after allogeneic HSCT. With a median follow-up of 22.7 months, the estimated 2-year OS and EFS are both 87.5%. Seven patients (87.5%) remain in continuous complete remission with sustained MRD negativity. Grade 3-4 neutropenia occurred in 57.1% of evaluable patients but was clinically manageable. This case series demonstrates that a low-dose chidamide maintenance regimen is feasible, well tolerated, and promising in this setting.

Indexed as

AminopyridinesBenzamidesHematopoietic Stem Cell TransplantationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultFemaleHumansMaintenance ChemotherapyMaleMiddle AgedTransplantation, HomologousYoung AdultAminopyridinesBenzamidesN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideallogeneic hematopoietic stem cell transplantationchidamidemaintenance therapyT‐ALL

Identifiers

PMID42446114
PMCPMC13367020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.